Silence Therapeutics plc Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Silence Therapeutics plc (SLNCF) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 20.88 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-03-05
- Silence Therapeutics plc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 20.88M shares, a 19.64% increase from fiscal 2024.
- Silence Therapeutics plc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 17.46M shares, a 10.10% increase from fiscal 2023.
- Silence Therapeutics plc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 15.85M shares, a 37.00% increase from fiscal 2022.
- Silence Therapeutics plc antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 11.57M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|
| 2025-12-31 | 20.88M shares 10-K · filed 2026-03-05 |
| 2024-12-31 | 17.46M shares 10-K · filed 2026-03-05 |
| 2023-12-31 | 15.85M shares 10-K · filed 2025-02-27 |
| 2022-12-31 | 11.57M shares 10-K · filed 2025-02-27 |